Meningococcal infection in modern realities

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

There is a narrative review of the state of the problem of meningococcal infection (MI) in the modern aspect. The significant list of the specifc features of the diseases and the unprecedented risk of the infection contributed to the development of a rational panel of vaccines for specific immunoprophylaxis. The cost of the disease, by taking into account the total cost of its hospital treatment and the expenditures of when disease-disabling consequences occur, is depicted, by using the real scenarios as an example. The review demonstrates considerable changes in the epidemiological manifestations of MI in the Russian Federation and presents a reasonable warning that there may be the next periodic rise in the incidence of MI.

Full Text

Restricted Access

About the authors

Irina S. Koroleva

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Author for correspondence.
Email: irina-korol@yandex.ru
ORCID iD: 0000-0003-0578-146X

MD; Head, Laboratory for the Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitides

Russian Federation, Moscow

Maria A. Kоroleva

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: korolevamaria389@gmail.com
ORCID iD: 0000-0002-2714-1191

MD; Senior Researcher, Laboratory for the Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitides

Russian Federation, Moscow

Nadejda S. Churilova

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: n27101996@yandex.ru
ORCID iD: 0000-0001-5344-5829

Junior Researcher, Laboratory for Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitides

Russian Federation, Moscow

Maria I. Gritsay

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: maria-griz@mail.ru
ORCID iD: 0000-0002-6288-9074

Cand. Med. Sci., Researcher, Laboratory for Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitides

Russian Federation, Moscow

Grigoriy V. Beloshitsky

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: g-belosh1@yandex.ru
ORCID iD: 0000-0002-4769-3890

Cand. Med. Sci., Senior Researcher, Laboratory for Epidemiology of Meningococcal Infection and Purulent Bacterial Meningitides

Russian Federation, Moscow

References

  1. Gotschlich E.C., Goldschneider I., Artenstein M.S. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J. Exp. Med. 1969; 129: 1367–84. doi: 10.1084/jem.129.6.1367
  2. Artenstein M.S., Gold R., Zimmerly J.G., Wyle F.A., Schneider H., Harkins С. Prevention of meningococcal disease by group C polysaccharide vaccines. N. Engl. J. Med. 1970; 282: 417–20. doi: 10.1056/NEJM197002192820803
  3. Dull P.M., McIntosh E.D. Meningococcal vaccine development – from glycoconjugates against MenACWY to proteins against MenB – potential for broad protection against meningococcal disease. Vaccine 2012; 30: B18–25. doi: 10.1016/j.vaccine.2012.01.062
  4. Vella M., Pace D. Glycoconjugate vaccines: an update. Expert Opin. Biol. Ther. 2015; 15: 529–46. doi: 10.1517/14712598.2015.993375
  5. Chen W.H., Neuzil K.M., Boyce C.R. ,Pasetti M.F., Reymann M.K., Martellet L. et al. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study. Lancet Infect. Dis. 2018; 18: 1088–96. doi: 10.1016/S1473-3099(18)30400-6
  6. Christodoulides M., Heckels J. Novel approaches to Neisseria meningitidis vaccine design. Pathog. Dis. 2018; 75: ftx033. doi: 10.1093/femspd/ftx033
  7. Sette A., Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 2010; 33: 530–41. doi: 10.1016/j.immuni.2010.09.017
  8. Rappuoli R., Pizza M., Masignani V., Vadivelu K. Meningococcal B vaccine (4CMenB): the journey from research to real world experience. Expert Rev. Vaccines 2018; 17: 1111–21. doi: 10.1080/14760584.2018.1547637
  9. Murphy E., Andrew L., Lee K.L., Dilts D.A., Nunez L., Fink P.S. et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J. Infect. Dis. 2009; 200: 379–89. doi: 10.1086/600141
  10. Perez J., Absalon J., Beeslaar J., Balmer P., Jansen K.U., Jones N.R et al. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine. Expert Rev. Vaccines. 2018; 17: 461–77. doi: 10.1080/14760584.2018.1483726
  11. Hoiseth S.K., Murphy E., Andrew L., Vogel U., Frosch M., Hellenbrand W. et al. A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups. Pediatr. Infect. Dis. J. 2013; 32: 1096–101. doi: 10.1097/INF.0b013e31829aa63b
  12. Rodrigues C.M.C., Lucidarme J., Borrow R., Smith A., Cameron J.C., Moxon E.R. et al. Genomic surveillance of 4CMenB vaccine antigenic variants among disease-causing Neisseria meningitidis isolates, United Kingdom, 2010–2016. Emerg. Infect. Dis. 2018; 24: 673–82. doi: 10.3201/eid2404.171480
  13. Jafri R.Z., Ali A., Messonnier N.E., Tevi-Benissan C., Durrheim D., Eskola J. et al. Global epidemiology of invasive meningococcal disease. Popul. Health Metr. 2013; (11): 17.
  14. Wang B., Santoreneos R., Giles L., Haji Ali Afzali H., Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine 2019; 37: 2768–82. doi: 10.1016/j.vaccine.2019.04.020
  15. Christensen H., May M., Bowen L., Hickman M., Trotter C.L. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect. Dis. 2010; (10): 853–61. doi: 10.1016/S1473-3099(10)70251-6
  16. Bénarda S., Wright C., Voisine J., Olivier C.W., Gaudelus J. Lifetime cost of meningococcal disease in France: Scenarios of severe meningitis and septicemia with purpura fulminans. Journal of Infection and Public Health 2016; (9): 339–47. doi: 10.1016/j.jiph.2015.10.016
  17. Wright C., Wordsworth R., Glennie L. Counting the Cost of Meningococcal Disease Scenarios of Severe Meningitis and Septicemia. Pediatr. Drugs 2013; 15: 49–58. doi: 10.1007/s40272-012-0006-0
  18. Darbà J., Kaskens L., Hark M., Wright C. Costs of surviving meningococcal disease in Spain: Evaluation for two cases of severe meningitis and septicaemia. Vaccine 2014; 32: 5006–12. doi: 10.1016/j.vaccine.2014.07.019
  19. О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2019 году: Государственный доклад. М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека. 2020. 340 с. [On the state of sanitary and epidemiological well-being of the population in the Russian Federation in 2019: State report]. Moscow, 2020. 340 p. (In Russ.).
  20. Костюкова Н.Н., Бехало В.А., Чернышова Т.Ф. Менингококковая инфекция в Российской Федерации: прошлое и ближайшие перспективы. Эпидемиология и инфекционные болезни 2014; (2): 73–9. Kostyukova N.N., Bekhalo V.A., Chernyshova T.F. [Meningococcal infection in the Russian Federation: past and immediate prospects]. Epidemiology and infectious diseases 2014; (2): 73–9. (In Russ.).
  21. Meningococcal vaccines: WHO position paper, November 2011. Weekly epidemiological record 2011; 47(86); 521–40. https://www.who. int/publications/i/item/WER8647

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. The incidence of Ml in the USSR and Russian Federation in 1966-2022.

Download (186KB)
Indexing metadata
3. Fig. 2. The frequency of the course of the Ml epidemic process in the Russian Federation in 1920-2022.

Download (92KB)
Indexing metadata

Copyright (c) 2023 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies